Clinical features of patients with CLL
. | Data . |
|---|---|
| No. of patients | 10 |
| Median age, y (range) | 55 (46-68) |
| No. of men (%) | 6 (60) |
| Rai stage at treatment, no. | |
| Intermediate risk (I/II) | 2 |
| High risk (III/IV) | 8 |
| Median WBC, × 109/L (range) | 42.3 (1.8-305) |
| Median Hgb, g/dL (range) | 11.3 (9.2-13.9) |
| Median platelets, × 109/L (range) | 84 (22-232) |
| Median ECOG performance status (range) | 1 (0-1) |
| Median no. of prior therapies (range) | 3 (1-7) |
| No. refractory to fludarabine | 10 |
| No. refractory to last therapy | 6 |
| Interphase cytogenetics, no.* | |
| Del(17)(p13.1) | 3 |
| Del(11)(q22.3) | 3* |
| Trisomy 12 | 0 |
| Del(13)(q14) | 2 |
| No abnormalities detected | 2 |
. | Data . |
|---|---|
| No. of patients | 10 |
| Median age, y (range) | 55 (46-68) |
| No. of men (%) | 6 (60) |
| Rai stage at treatment, no. | |
| Intermediate risk (I/II) | 2 |
| High risk (III/IV) | 8 |
| Median WBC, × 109/L (range) | 42.3 (1.8-305) |
| Median Hgb, g/dL (range) | 11.3 (9.2-13.9) |
| Median platelets, × 109/L (range) | 84 (22-232) |
| Median ECOG performance status (range) | 1 (0-1) |
| Median no. of prior therapies (range) | 3 (1-7) |
| No. refractory to fludarabine | 10 |
| No. refractory to last therapy | 6 |
| Interphase cytogenetics, no.* | |
| Del(17)(p13.1) | 3 |
| Del(11)(q22.3) | 3* |
| Trisomy 12 | 0 |
| Del(13)(q14) | 2 |
| No abnormalities detected | 2 |
Hgb indicates hemoglobin.
Dohner prioritization schema used to categorize patients with multiple abnormalities [(17)(p13.1)> del(11)(q22.3)> +12 > del(13)(q14)].